Second primary malignancies in treated and untreated patients with chronic lymphocytic leukemiaMoritz Fürstenau, Anna‐Maria Fink, Michael Koenigsmann et al.|American Journal of Hematology|2021Cited by 9
Bendamustine Plus Rituximab Followed By Rituximab Maintenance for Patients with Untreated Advanced Follicular Lymphomas. Results from the StiL NHL 7-2008 Trial (MAINTAIN trial) (ClinicalTrials.gov Identifier: NCT00877214)Mathias Rummel, Wolfram Brugger, Andreas Viardot et al.|Blood|2014Cited by 7
Four versus Two Years of Rituximab Maintenance (R-Maintenance) Following Bendamustine Plus Rituximab (B-R): Results of a Prospective, Randomized Multicenter Phase 3 Study in First-Line Follicular Lymphoma (the StiL NHL7-2008 MAINTAIN Study)Mathias Rummel, Richard Greil, Christian Buske et al.|Clinical Lymphoma Myeloma & Leukemia|2018Cited by 6
Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive post-remission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemiaSonia Jaramillo, Richard F. Schlenk, Johannes Krisam et al.|Haematologica|2024Cited by 1
Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL - an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 TrialKonstantinos Christofyllakis, Mathias Rummel, Igor Age Kos et al.|Blood|2024Cited by 0